ATE417628T1 - Topisch anwendbare pharmazeutische zubereitung - Google Patents

Topisch anwendbare pharmazeutische zubereitung

Info

Publication number: ATE417628T1
Authority: AT; Austria
Prior art keywords: pharmaceutical preparation; topically applicable; applicable pharmaceutical; topically; administering
Prior art date: 2002-05-28

Application number

AT03755048T

Other languages

English (en)

Inventor

Christina Bolle

Rudolf Linder

Original Assignee

Nycomed Gmbh

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-05-28

Filing date

2003-05-27

Publication date

2009-01-15

2003-05-27 Application filed by Nycomed Gmbh filed Critical Nycomed Gmbh

2009-01-15 Application granted granted Critical

2009-01-15 Publication of ATE417628T1 publication Critical patent/ATE417628T1/de

Links

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/08—Antiseborrheics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
- F41—WEAPONS
- F41B—WEAPONS FOR PROJECTING MISSILES WITHOUT USE OF EXPLOSIVE OR COMBUSTIBLE PROPELLANT CHARGE; WEAPONS NOT OTHERWISE PROVIDED FOR
- F41B5/00—Bows; Crossbows
- F41B5/12—Crossbows
- F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
- F41—WEAPONS
- F41B—WEAPONS FOR PROJECTING MISSILES WITHOUT USE OF EXPLOSIVE OR COMBUSTIBLE PROPELLANT CHARGE; WEAPONS NOT OTHERWISE PROVIDED FOR
- F41B5/00—Bows; Crossbows
- F41B5/12—Crossbows
- F41B5/123—Compound crossbows
- F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
- F41—WEAPONS
- F41B—WEAPONS FOR PROJECTING MISSILES WITHOUT USE OF EXPLOSIVE OR COMBUSTIBLE PROPELLANT CHARGE; WEAPONS NOT OTHERWISE PROVIDED FOR
- F41B5/00—Bows; Crossbows
- F41B5/14—Details of bows; Accessories for arc shooting
- F41B5/1442—Accessories for arc or bow shooting
- F41B5/1469—Bow-string drawing or releasing devices

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Epidemiology (AREA)
Dermatology (AREA)
Ophthalmology & Optometry (AREA)
Pulmonology (AREA)
Immunology (AREA)
General Engineering & Computer Science (AREA)
Otolaryngology (AREA)
Rheumatology (AREA)
Physical Education & Sports Medicine (AREA)
Biomedical Technology (AREA)
Dispersion Chemistry (AREA)
Heart & Thoracic Surgery (AREA)
Communicable Diseases (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Toxicology (AREA)
Oncology (AREA)
Orthopedic Medicine & Surgery (AREA)
Pain & Pain Management (AREA)
Cardiology (AREA)
Vascular Medicine (AREA)
Oil, Petroleum & Natural Gas (AREA)
Urology & Nephrology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)

AT03755048T 2002-05-28 2003-05-27 Topisch anwendbare pharmazeutische zubereitung ATE417628T1 (de)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
DE10223828		2002-05-28
EP02011830		2002-05-28
DE10311613		2003-03-14

Publications (1)

Publication Number	Publication Date
ATE417628T1 true ATE417628T1 (de)	2009-01-15

Family

ID=29587313

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
AT03730122T ATE485821T1 (de)	2002-05-28	2003-05-27	Ophthalmologische zubereitung enthaltend roflumilast in der behandlung von krankheiten der augen
AT03755048T ATE417628T1 (de)	2002-05-28	2003-05-27	Topisch anwendbare pharmazeutische zubereitung

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
AT03730122T ATE485821T1 (de)	2002-05-28	2003-05-27	Ophthalmologische zubereitung enthaltend roflumilast in der behandlung von krankheiten der augen

Country Status (33)

Country	Link
US (7)	US20060084685A1 (de)
EP (3)	EP2020243B1 (de)
JP (3)	JP5652983B2 (de)
KR (2)	KR101307093B1 (de)
CN (3)	CN101491520B (de)
AT (2)	ATE485821T1 (de)
AU (2)	AU2003240719B2 (de)
BR (2)	BR0311337A (de)
CA (2)	CA2486910C (de)
CY (2)	CY1110312T1 (de)
DE (2)	DE60325354D1 (de)
DK (3)	DK2020243T3 (de)
EA (2)	EA020569B1 (de)
ES (3)	ES2354971T3 (de)
HK (2)	HK1079437A1 (de)
HR (1)	HRP20041211B1 (de)
HU (1)	HUE039709T2 (de)
IL (3)	IL164935A (de)
IS (1)	IS2639B (de)
LT (1)	LT2020243T (de)
MA (1)	MA27813A1 (de)
ME (1)	ME00565A (de)
MX (2)	MXPA04011612A (de)
NO (2)	NO334882B1 (de)
NZ (3)	NZ536920A (de)
PL (3)	PL212134B1 (de)
PT (3)	PT2020243T (de)
RS (1)	RS51104B (de)
SI (2)	SI2020243T1 (de)
TR (1)	TR201815573T4 (de)
UA (2)	UA81910C2 (de)
WO (2)	WO2003099278A1 (de)
ZA (2)	ZA200408649B (de)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6872382B1 (en)	2001-05-21	2005-03-29	Alcon, Inc.	Use of selective PDE IV inhibitors to treat dry eye disorders
MY140561A (en) *	2002-02-20	2009-12-31	Nycomed Gmbh	Dosage form containing pde 4 inhibitor as active ingredient
DK2020243T3 (en) *	2002-05-28	2018-11-19	Astrazeneca Ab	Pharmaceutical composition which can be applied topically
EP1542768A1 (de)	2002-09-20	2005-06-22	Alcon, Inc.	Verwendung von zytokin-synthesehemmern zur behandlung von erkrankungen mit trockenem auge
FR2851247B1 (fr) *	2003-02-19	2007-06-29	Exonhit Therapeutics Sa	Methodes et compositions pour le traitement de pathologies degeneratives oculaires
EP1606261B1 (de)	2003-03-10	2009-11-04	Nycomed GmbH	Neues verfahren zur herstellung vonroflumilast
JP2007517893A (ja) *	2004-01-10	2007-07-05	バイオリピッドインコーポレイテッド	脂質組成物及び該脂質組成物の使用方法
DE102004046235A1 (de) *	2004-09-22	2006-03-30	Altana Pharma Ag	Arzneimittelzubereitung
DE102004046236A1 (de) *	2004-09-22	2006-03-30	Altana Pharma Ag	Arzneimittelzubereitung
AU2006222060B2 (en) *	2005-03-08	2011-09-01	Takeda Gmbh	Roflumilast for the treatment of diabetes mellitus
CA2601250C (en) *	2005-03-16	2014-10-28	Nycomed Gmbh	Taste masked dosage form containing roflumilast
US20090209599A1 (en) *	2005-06-09	2009-08-20	Yoko Endo	Eye drop containing roflumilast
WO2007097317A1 (ja)	2006-02-21	2007-08-30	Eisai R & D Management Co., Ltd.	４－（３－ベンゾイルアミノフェニル）－６，７－ジメトキシ－２－メチルアミノキナゾリン誘導体
AU2008215411B2 (en)	2007-02-16	2012-11-22	Eisai R & D Management Co., Ltd.	Crystal, amorphous form and salt of methyl N-[3-(6,7-dimethoxy- 2-methylaminoquinazolin-4-yl)phenyl]terephthalamic acid
CA2696727A1 (en)	2007-08-17	2009-02-26	Eisai R&D Management Co., Ltd.	Method for producing quinazoline derivative
CN101687819B (zh)	2007-08-17	2013-03-20	卫材R&D管理有限公司	外用剂
BR112012010179A2 (pt)	2009-10-30	2015-09-29	Nestec Sa	métodos para manter a saúde do olho e melhorar as doenças oftálmicas em caninos.
ES2408132B1 (es) *	2010-09-08	2014-04-04	Universidad Miguel Hernández De Elche	Composición farmacéutica para el tratamiento de la epífora.
ES2377785B2 (es) *	2010-09-08	2012-09-26	Universidad Miguel Hernández De Elche	Composición farmacéutica para el tratamiento del ojo seco.
ES2868231T3 (es)	2011-03-07	2021-10-21	Amgen Europe Gmbh	Métodos de tratamiento de enfermedades usando compuestos de isoindolina
CN102793684B (zh) *	2011-05-26	2016-02-17	杭州赛利药物研究所有限公司	罗氟司特液体制剂及其制备方法
PE20141031A1 (es) *	2011-06-28	2014-08-21	Bayer Healthcare Llc	Composicion farmaceutica oftalmologica topica que contiene regorafenib
EP2836240B1 (de) *	2012-04-10	2019-03-13	Georgia State University Research Foundation, Inc.	Zusammensetzungen und verfahren zur behandlung von mittelohrentzündung und anderen erkrankungen mit cyld-inhibitoren
CN103570610B (zh) *	2012-07-18	2017-08-11	重庆华邦制药有限公司	一种罗氟司特微粒的制备方法
WO2014012954A1 (en)	2012-07-18	2014-01-23	Takeda Gmbh	Treatment of partly controlled or uncontrolled severe asthma
US9737521B2 (en)	2012-11-08	2017-08-22	Rhizen Pharmaceuticals Sa	Pharmaceutical compositions containing a PDE4 inhibitor and a PI3 delta or dual PI3 delta-gamma kinase inhibitor
DK3033082T3 (da)	2013-08-16	2021-09-20	Univ Maastricht	Behandling af kognitiv svækkelse med pde4-hæmmer
CN105434328A (zh) *	2014-09-01	2016-03-30	天津药物研究院有限公司	一种含罗氟司特固体分散体的固体制剂及其制备方法
EP3210974B1 (de) *	2014-10-24	2020-01-29	Hisamitsu Pharmaceutical Co., Inc.	Prodrug von roflumilast
CN104997959A (zh) *	2015-08-21	2015-10-28	蔡宇平	一种用于治疗睑板腺囊肿的中药
CN106148528B (zh) *	2016-07-11	2019-10-01	赵晨	一种遗传性Usher综合征的致病突变及其检测试剂
US20210161870A1 (en)	2017-06-07	2021-06-03	Arcutis Biotherapeutics, Inc.	Roflumilast formulations with an improved pharmacokinetic profile
US11129818B2 (en)	2017-06-07	2021-09-28	Arcutis Biotherapeutics, Inc.	Topical roflumilast formulation having improved delivery and plasma half life
US12011437B1 (en)	2017-06-07	2024-06-18	Arcutis Biotherapeutics, Inc.	Roflumilast formulations with an improved pharmacokinetic profile
US20200155524A1 (en) *	2018-11-16	2020-05-21	Arcutis, Inc.	Method for reducing side effects from administration of phosphodiesterase-4 inhibitors
US12042487B2 (en)	2018-11-16	2024-07-23	Arcutis Biotherapeutics, Inc.	Method for reducing side effects from administration of phosphodiesterase-4 inhibitors
US9895359B1 (en)	2017-06-07	2018-02-20	Arcutis, Inc.	Inhibition of crystal growth of roflumilast
US11534493B2 (en) *	2017-09-22	2022-12-27	Arcutis Biotherapeutics, Inc.	Pharmaceutical compositions of roflumilast in aqueous blends of water-miscible, pharmaceutically acceptable solvents
CN108283620A (zh) *	2018-03-13	2018-07-17	兆科药业（广州）有限公司	一种磷酸二酯酶-4抑制剂的局部药物组合物及其制备方法
EP3801461A2 (de)	2018-06-04	2021-04-14	Arcutis, Inc.	Verfahren und formulierung zur verbesserung der hautdurchdringungsverzögerungszeit von roflumilast
KR102117525B1 (ko) *	2018-07-09	2020-06-01	건양대학교 산학협력단	Pde4b 저해제를 유효성분으로 함유하는 만성 부비동염에서의 비용종 발생의 예방 및 치료용 약학 조성물
CN115551478A (zh)	2020-01-31	2022-12-30	阿尔库缇斯生物疗法股份有限公司	具有改善递送和血浆半衰期的罗氟司特局部制剂
AU2021268977B2 (en) *	2020-05-07	2024-05-23	Arcutis Biotherapeutics, Inc.	Treatment of skin conditions using high Krafft temperature anionic surfactants
WO2022169615A1 (en)	2021-02-05	2022-08-11	Arcutis Biotherapeutics, Inc.	Roflumilast formulations with an improved pharmacokinetic profile
AU2022218993A1 (en) *	2021-02-10	2023-08-03	Iolyx Therapeutics, Inc.	Methods for ophthalmic delivery of roflumilast
CN116867480A (zh) *	2021-02-10	2023-10-10	洛利克斯治疗有限公司	眼部递送罗氟司特的方法
EP4351612A2 (de) *	2021-06-01	2024-04-17	Eyedea Bio, Llc	System zur verabreichung von arzneimitteln mit verlängerter freisetzung für augenarzneimittel und verfahren zur verwendung
AU2022353032A1 (en) *	2021-09-22	2024-03-28	Iolyx Therapeutics, Inc.	Methods of treating ocular inflammatory diseases
US20240108609A1 (en)	2022-09-15	2024-04-04	Arcutis Biotherapeutics, Inc.	Pharmaceutical compositions of roflumilast and solvents capable of dissolving high amounts of the drug

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4753945A (en) *	1986-02-19	1988-06-28	Eye Research Institute Of Retina Foundation	Stimulation of tear secretion with phosphodiesterase inhibitors
US5011843A (en) *	1988-05-31	1991-04-30	Iolab Corporation	Treatment of glaucoma using phosphodiesterase inhibitors
US5891904A (en) *	1992-09-14	1999-04-06	Wolf-Georg Forssmann	Use of inhibitors of phosphodiesterase IV
ES2176252T3 (es) *	1993-07-02	2002-12-01	Altana Pharma Ag	Benzamidas sustituidas con fluoro-alcoxi y su utilizacion como agentes inhibidores de fosfodiesterasas de nucleotidos ciclicos.
CN1128955A (zh) *	1993-08-10	1996-08-14	藤泽药品工业株式会社	经皮吸收制剂
ZA954599B (en) *	1994-06-07	1996-01-26	Allergan Inc	Stable gel formulation for topical treatment of skin conditions
HUP0103947A3 (en) *	1998-09-29	2002-06-28	Fujisawa Pharmaceutical Co	Novel methanesulfonate salts of pyridopyrazine compound and crystals thereof and their pharmaceutical use
US6395746B1 (en) *	1998-09-30	2002-05-28	Alcon Manufacturing, Ltd.	Methods of treating ophthalmic, otic and nasal infections and attendant inflammation
US20020006418A1 (en) *	1998-10-13	2002-01-17	John Kung	Composition to enhance permeation of topical skin agents
DE60015098T2 (de)	1999-03-10	2006-02-02	Altana Pharma Ag	3-cyclopropylmethoxy-4-difluormethoxy-n-(3,5-dichlor-pyrid-4-yl)-benzamid zur behandlung von multipler sklerose
US6174878B1 (en) *	1999-08-31	2001-01-16	Alcon Laboratories, Inc.	Topical use of kappa opioid agonists to treat otic pain
JP2003513038A (ja) *	1999-10-29	2003-04-08	スミスクライン・ビーチャム・コーポレイション	ホスホジエステラーゼ４阻害剤の投与法
MXPA02007465A (es) *	2000-01-31	2002-12-13	Pfizer Prod Inc	Carboxamidas de pirimidina utiles como inhibidores de isozimas pde4.
EP1261331A4 (de) *	2000-02-16	2005-01-05	Univ Nebraska Medical Ct	Methoden und zusammenstellungen zur behandlung von fibrotischen erkrankungen
JP2003534328A (ja) *	2000-05-25	2003-11-18	メルクフロストカナダアンドカンパニー	フルオロアルコキシ置換ベンズアミドジクロロピリジニルｎ−オキシドｐｄｅ４阻害剤
CA2427814C (en) *	2000-11-07	2009-06-02	Merck & Co., Inc.	A combination of a pde4 inhibitor and a leukotriene antagonist in the treatment of bronchial and respiratory disorders
UA77656C2 (en) *	2001-04-07	2007-01-15	Glaxo Group Ltd	S-fluoromethyl ester of 6-alpha, 9-alpha-difluoro-17-alpha-[(2-furanylcarbonyl)oxy]-11-beta-hydroxy-16- alpha-methyl-3-oxoandrosta-1,4-dien-17-beta-carbothioacid as anti-inflammatory agent
US6872382B1 (en) *	2001-05-21	2005-03-29	Alcon, Inc.	Use of selective PDE IV inhibitors to treat dry eye disorders
US20030092706A1 (en) *	2001-11-09	2003-05-15	Johannes Barsig	Combination
DK2020243T3 (en) *	2002-05-28	2018-11-19	Astrazeneca Ab	Pharmaceutical composition which can be applied topically

2003
- 2003-05-27 DK DK08166780.0T patent/DK2020243T3/en active
- 2003-05-27 ES ES03730122T patent/ES2354971T3/es not_active Expired - Lifetime
- 2003-05-27 UA UA20041210683A patent/UA81910C2/uk unknown
- 2003-05-27 UA UAA200712909A patent/UA88523C2/ru unknown
- 2003-05-27 NZ NZ536920A patent/NZ536920A/en not_active IP Right Cessation
- 2003-05-27 DK DK03755048T patent/DK1511516T3/da active
- 2003-05-27 NZ NZ553731A patent/NZ553731A/en not_active IP Right Cessation
- 2003-05-27 EP EP08166780.0A patent/EP2020243B1/de not_active Expired - Lifetime
- 2003-05-27 US US10/515,896 patent/US20060084685A1/en not_active Abandoned
- 2003-05-27 MX MXPA04011612A patent/MXPA04011612A/es active IP Right Grant
- 2003-05-27 PL PL372095A patent/PL212134B1/pl unknown
- 2003-05-27 NZ NZ537308A patent/NZ537308A/en not_active IP Right Cessation
- 2003-05-27 AU AU2003240719A patent/AU2003240719B2/en not_active Ceased
- 2003-05-27 WO PCT/EP2003/005536 patent/WO2003099278A1/en active Application Filing
- 2003-05-27 LT LTEP08166780.0T patent/LT2020243T/lt unknown
- 2003-05-27 SI SI200332580T patent/SI2020243T1/sl unknown
- 2003-05-27 MX MXPA04011528A patent/MXPA04011528A/es active IP Right Grant
- 2003-05-27 HU HUE08166780A patent/HUE039709T2/hu unknown
- 2003-05-27 EP EP03755048A patent/EP1511516B1/de not_active Expired - Lifetime
- 2003-05-27 CA CA2486910A patent/CA2486910C/en not_active Expired - Fee Related
- 2003-05-27 WO PCT/EP2003/005524 patent/WO2003099334A1/en active Application Filing
- 2003-05-27 DE DE60325354T patent/DE60325354D1/de not_active Expired - Lifetime
- 2003-05-27 PL PL397021A patent/PL397021A1/pl unknown
- 2003-05-27 PT PT08166780T patent/PT2020243T/pt unknown
- 2003-05-27 ES ES03755048T patent/ES2319517T3/es not_active Expired - Lifetime
- 2003-05-27 EA EA200702588A patent/EA020569B1/ru not_active IP Right Cessation
- 2003-05-27 JP JP2004506857A patent/JP5652983B2/ja not_active Expired - Lifetime
- 2003-05-27 AU AU2003232828A patent/AU2003232828B2/en not_active Ceased
- 2003-05-27 KR KR1020117025130A patent/KR101307093B1/ko not_active IP Right Cessation
- 2003-05-27 DK DK03730122.3T patent/DK1511481T3/da active
- 2003-05-27 BR BR0311337-0A patent/BR0311337A/pt not_active Application Discontinuation
- 2003-05-27 CN CN2009100043805A patent/CN101491520B/zh not_active Expired - Fee Related
- 2003-05-27 CN CNB038120941A patent/CN100490804C/zh not_active Expired - Fee Related
- 2003-05-27 PT PT03755048T patent/PT1511516E/pt unknown
- 2003-05-27 AT AT03730122T patent/ATE485821T1/de active
- 2003-05-27 JP JP2004506802A patent/JP2005529928A/ja active Pending
- 2003-05-27 EA EA200401517A patent/EA010416B1/ru not_active IP Right Cessation
- 2003-05-27 PT PT03730122T patent/PT1511481E/pt unknown
- 2003-05-27 ME MEP-854/08A patent/ME00565A/xx unknown
- 2003-05-27 AT AT03755048T patent/ATE417628T1/de active
- 2003-05-27 EP EP03730122A patent/EP1511481B1/de not_active Expired - Lifetime
- 2003-05-27 KR KR10-2004-7019272A patent/KR20050014844A/ko not_active Application Discontinuation
- 2003-05-27 DE DE60334692T patent/DE60334692D1/de not_active Expired - Lifetime
- 2003-05-27 US US10/515,698 patent/US20060084684A1/en not_active Abandoned
- 2003-05-27 TR TR2018/15573T patent/TR201815573T4/tr unknown
- 2003-05-27 RS YUP-1014/04A patent/RS51104B/sr unknown
- 2003-05-27 CA CA2486917A patent/CA2486917C/en not_active Expired - Fee Related
- 2003-05-27 ES ES08166780.0T patent/ES2693094T3/es not_active Expired - Lifetime
- 2003-05-27 CN CN038124068A patent/CN1655823B/zh not_active Expired - Fee Related
- 2003-05-27 PL PL372082A patent/PL211870B1/pl unknown
- 2003-05-27 SI SI200331532T patent/SI1511516T1/sl unknown
- 2003-05-27 BR BR0311339-6A patent/BR0311339A/pt not_active Application Discontinuation
2004
- 2004-10-21 MA MA27912A patent/MA27813A1/fr unknown
- 2004-10-26 ZA ZA200408649A patent/ZA200408649B/xx unknown
- 2004-10-31 IL IL164935A patent/IL164935A/en not_active IP Right Cessation
- 2004-11-07 IL IL165065A patent/IL165065A/en active IP Right Grant
- 2004-11-26 ZA ZA200409584A patent/ZA200409584B/xx unknown
- 2004-12-16 NO NO20045506A patent/NO334882B1/no not_active IP Right Cessation
- 2004-12-23 IS IS7612A patent/IS2639B/is unknown
- 2004-12-27 NO NO20045656A patent/NO334916B1/no not_active IP Right Cessation
- 2004-12-27 HR HRP20041211AA patent/HRP20041211B1/hr not_active IP Right Cessation
2005
- 2005-12-14 HK HK05111481.8A patent/HK1079437A1/xx not_active IP Right Cessation
- 2005-12-16 HK HK05111628.2A patent/HK1079445A1/xx not_active IP Right Cessation
2008
- 2008-04-29 US US12/149,250 patent/US20080280958A1/en not_active Abandoned
2009
- 2009-03-10 CY CY20091100273T patent/CY1110312T1/el unknown
2010
- 2010-11-30 IL IL209657A patent/IL209657A0/en unknown
2011
- 2011-08-26 US US13/219,056 patent/US20110313005A1/en not_active Abandoned
2012
- 2012-07-09 JP JP2012154020A patent/JP5683538B2/ja not_active Expired - Lifetime
2013
- 2013-11-08 US US14/075,035 patent/US20140303215A1/en not_active Abandoned
2018
- 2018-10-03 US US16/150,759 patent/US20190029956A1/en not_active Abandoned
- 2018-10-24 CY CY181101093T patent/CY1121133T1/el unknown
2020
- 2020-06-03 US US16/891,823 patent/US20210116207A1/en not_active Abandoned

Also Published As

Publication number	Publication date
HRP20041211A2 (hr)	2006-04-30
JP2005529930A (ja)	2005-10-06
PT1511481E (pt)	2011-01-14
DE60325354D1 (de)	2009-01-29
KR101307093B1 (ko)	2013-09-11
EA020569B1 (ru)	2014-12-30
JP2005529928A (ja)	2005-10-06
HUE039709T2 (hu)	2019-01-28
CA2486910C (en)	2011-11-29
SI2020243T1 (sl)	2018-11-30
PL372082A1 (en)	2005-07-11
US20110313005A1 (en)	2011-12-22
JP5683538B2 (ja)	2015-03-11
PL212134B1 (pl)	2012-08-31
CA2486910A1 (en)	2003-12-04
NZ536920A (en)	2007-04-27
NO334882B1 (no)	2014-06-30
NO20045506L (no)	2004-12-16
CN101491520A (zh)	2009-07-29
CA2486917C (en)	2011-11-22
IS7612A (is)	2004-12-23
SI1511516T1 (sl)	2009-06-30
EA200401517A1 (ru)	2005-06-30
BR0311337A (pt)	2005-03-15
EP1511516B1 (de)	2008-12-17
BR0311339A (pt)	2005-03-22
IL165065A (en)	2010-11-30
AU2003232828B2 (en)	2010-06-24
CN101491520B (zh)	2011-03-16
US20210116207A1 (en)	2021-04-22
HRP20041211B1 (hr)	2013-06-30
DK2020243T3 (en)	2018-11-19
LT2020243T (lt)	2018-11-12
US20080280958A1 (en)	2008-11-13
KR20050014844A (ko)	2005-02-07
CA2486917A1 (en)	2003-12-04
ATE485821T1 (de)	2010-11-15
IL164935A (en)	2010-12-30
NZ537308A (en)	2009-09-25
AU2003232828A1 (en)	2003-12-12
PL397021A1 (pl)	2012-03-26
PL211870B1 (pl)	2012-07-31
CY1121133T1 (el)	2019-12-11
WO2003099334A1 (en)	2003-12-04
CN1655823B (zh)	2010-05-26
EP2020243B1 (de)	2018-08-15
PT2020243T (pt)	2018-11-09
CY1110312T1 (el)	2015-01-14
ES2354971T3 (es)	2011-03-21
WO2003099278A1 (en)	2003-12-04
UA88523C2 (ru)	2009-10-26
CN1655782A (zh)	2005-08-17
AU2003240719B2 (en)	2009-12-10
EA200702588A1 (ru)	2008-08-29
AU2003240719A1 (en)	2003-12-12
US20140303215A1 (en)	2014-10-09
EP1511481A1 (de)	2005-03-09
IS2639B (is)	2010-06-15
CN100490804C (zh)	2009-05-27
JP2012229245A (ja)	2012-11-22
HK1079445A1 (en)	2006-04-07
TR201815573T4 (tr)	2018-11-21
HK1079437A1 (en)	2006-04-07
DE60334692D1 (de)	2010-12-09
PL372095A1 (en)	2005-07-11
IL209657A0 (en)	2011-02-28
PT1511516E (pt)	2009-02-20
ZA200408649B (en)	2007-12-27
UA81910C2 (uk)	2008-02-25
RS51104B (sr)	2010-10-31
US20060084684A1 (en)	2006-04-20
US20060084685A1 (en)	2006-04-20
NO20045656L (no)	2004-12-27
ES2693094T3 (es)	2018-12-07
EP1511516A1 (de)	2005-03-09
DK1511481T3 (da)	2011-01-24
IL165065A0 (en)	2005-12-18
EA010416B1 (ru)	2008-08-29
EP1511481B1 (de)	2010-10-27
EP2020243A1 (de)	2009-02-04
DK1511516T3 (da)	2009-04-06
MXPA04011612A (es)	2005-03-07
MA27813A1 (fr)	2006-04-03
JP5652983B2 (ja)	2015-01-14
KR20110122230A (ko)	2011-11-09
RS101404A (en)	2007-02-05
NO334916B1 (no)	2014-07-14
CN1655823A (zh)	2005-08-17
IL164935A0 (en)	2005-12-18
MXPA04011528A (es)	2005-02-14
NZ553731A (en)	2007-07-27
ME00565A (en)	2011-12-20
US20190029956A1 (en)	2019-01-31
ZA200409584B (en)	2006-05-31
ES2319517T3 (es)	2009-05-08

Legal Events

Date

Code

Title

Description

2009-07-15

UEP

Publication of translation of european patent specification

Ref document number: 1511516

Country of ref document: EP

Publication	Publication Date	Title
CY1121133T1 (el)	2019-12-11	Τοπικα εφαρμοσιμο φαρμακευτικο παρασκευασμα
NO20032510D0 (no)	2003-06-03	Organiske forbindelser
ATE337016T1 (de)	2006-09-15	Zusammensetzungen zur erhöhung der bioverfügbarkeit von oral verabreichten pharmazeutischen verbindungen
PA8589401A1 (es)	2004-07-20	Derivados de indolilo
ECSP045447A (es)	2005-01-28	Preparación farmacéutica que se puede aplicar por vía tópica